Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

HYTN Innovations Inc C.HYTN

HYTN Innovations Inc. is a Canada-based company that creates products containing psychoactive and psychotropic compounds, including cannabinoids derived from cannabis. The Company formulates, manufactures, markets, and sells cannabis goods. It is engaged in the development of the sparkling tetrahydrocannabinol and the cannabidiol beverage business. All its sparkling cannabis beverages contain 10 milligrams (mg) of THC and are made using its process, Elevation Technology. Its products include Rosewater Lemonade, Watermelon Mint, Lemongrass Ginger, and Blood Orange. Its Rosewater Lemonade is a sugar-free exploration of citrus accented with floral notes. Blood Orange is formulated to bring out the sweet flavors found in this seasonal citrus fruit. Its activities are focused on a single production and manufacturing facility, based in Kelowna, British Columbia. The Company’s subsidiaries include HYTN Innovations Inc., HYTN Beverage Corp, HYTN Cannabis Inc., and 1306562 B.C. Ltd.


CSE:HYTN - Post by User

Post by Betteryear2on Apr 03, 2024 8:15am
40 Views
Post# 35967083

HYTN Provides Corporate Update

HYTN Provides Corporate UpdateVANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0, "HYTN" or "The Company"), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to provide an update on the company’s new strategic goals and plans for global commercialization. This follows the recent achievement of Good Manufacturing Practices (GMP) certification for HYTN's Kelowna production facility by Australia's Therapeutic Goods Administration (TGA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standard.

HYTN Provides Corporate Update, Outlines New Global (globenewswire.com)
<< Previous
Bullboard Posts
Next >>